150 related articles for article (PubMed ID: 1598949)
1. Summary of the ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics.
Am J Hosp Pharm; 1992 Mar; 49(3):652-4. PubMed ID: 1598949
[No Abstract] [Full Text] [Related]
2. ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics.
Clin Pharm; 1992 Feb; 11(2):117-36. PubMed ID: 1312920
[No Abstract] [Full Text] [Related]
3. ASHP guidelines on formulary system management.
Am J Hosp Pharm; 1992 Mar; 49(3):648-52. PubMed ID: 1598948
[No Abstract] [Full Text] [Related]
4. ASHP guidelines for hospital formularies.
Am J Hosp Pharm; 1978 Mar; 35(3):326-8. PubMed ID: 626216
[No Abstract] [Full Text] [Related]
5. ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis. ASHP Commission on Therapeutics.
Clin Pharm; 1990 Jun; 9(6):423-45. PubMed ID: 2194737
[No Abstract] [Full Text] [Related]
6. Summary of the ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis. ASHP Commission on Therapeutics.
Am J Hosp Pharm; 1990 Jul; 47(7):1618-21. PubMed ID: 2114793
[No Abstract] [Full Text] [Related]
7. ASHP technical assistance bulletin on hospital formularies.
Am J Hosp Pharm; 1985 Feb; 42(2):375-7. PubMed ID: 3976687
[No Abstract] [Full Text] [Related]
8. ASHP technical assistance bulletin on assessing cost-containment strategies for institutional pharmacies.
Am J Hosp Pharm; 1985 Jul; 42(7):1583-91. PubMed ID: 4025363
[No Abstract] [Full Text] [Related]
9. ASHP statement on the formulary system.
Am J Hosp Pharm; 1983 Aug; 40(8):1384-5. PubMed ID: 6614023
[No Abstract] [Full Text] [Related]
10. ASHP statement on the formulary system.
Am J Hosp Pharm; 1986 Nov; 43(11):2839-41. PubMed ID: 3799624
[No Abstract] [Full Text] [Related]
11. History and status of the ASHP drug coding and listing services.
Provost GP
Am J Hosp Pharm; 1968 Jan; 25(1):12-9. PubMed ID: 4867618
[No Abstract] [Full Text] [Related]
12. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. ASHP Commission on Therapeutics.
Clin Pharm; 1992 Jun; 11(6):483-513. PubMed ID: 1600684
[No Abstract] [Full Text] [Related]
13. Current information on the use of immunobiologics: comments of the ASHP Commission on Therapeutics.
Lipman AG
Clin Pharm; 1989 Dec; 8(12):850-1. PubMed ID: 2598609
[No Abstract] [Full Text] [Related]
14. ASHP comments on proposed federal conditions of participation for hospitals.
Am J Hosp Pharm; 1983 Jun; 40(6):1037-41. PubMed ID: 6346868
[No Abstract] [Full Text] [Related]
15. Editorial: The ASHP council on clinical pharmacy and therapeutics.
Zellmer WA
Am J Hosp Pharm; 1974 Sep; 31(9):831. PubMed ID: 4423139
[No Abstract] [Full Text] [Related]
16. Promoting rational drug use through the ASHP Commission on Therapeutics.
Witmer DR
Am J Hosp Pharm; 1994 Jun; 51(12):1536. PubMed ID: 8092154
[No Abstract] [Full Text] [Related]
17. Intravenous immune globulin.
Med Lett Drugs Ther; 1992 Dec; 34(886):116-8. PubMed ID: 1465040
[No Abstract] [Full Text] [Related]
18. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immune globulin for multiple sclerosis.
Tecnologica; 1995 May; ():10. PubMed ID: 10168292
[TBL] [Abstract][Full Text] [Related]
20. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012.
Robert P; Hotchko M
Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899
[No Abstract] [Full Text] [Related]
[Next] [New Search]
